Explore the Relationship Between Heart Rate Variability, Body Mass Index, Inflammation, and Insulin Resistance.

Obesity Clinical Trial

Official title:

Explore the Relationship Between Heart Rate Variability, Body Mass Index, Inflammation, and Insulin Resistance: From a Population-based Survey to Multi-arms of Aerobic Exercise Intervention.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05949710
• Other study ID #: NTJCN
• Status: Recruiting
• Phase: N/A
• Start date: September 11, 2023
• Est. completion date: July 31, 2024

Study information

• Verified date: November 2023
• Source: National Tainan Junior College of Nursing
• Contact: Yu-Hsuan Chang, phD
• Phone: 01188662110600
• Email: fiona5252[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The findings will serve as a reference for clinical professionals to promote exercise among the general population and will provide evidence of whether different exercise amounts are recommended for individuals with different BMIs for improving HRV.

Description:

Background: Heart rate variability (HRV) measurement is widely used to assess the function of cardiac autonomic modulation. Aerobic exercise (AE) has been proven to improve HRV. However, because HRV is highly associated with visceral fat, inflammatory status, and insulin resistance, whether baseline body inflammation status can explain the heterogeneous response to AE remains unknown. Purposes: We will (1) compare the effects of AE training in improving HRV, inflammatory markers, and insulin resistance between community residents with normal weight and overweight and (2) compare the effects of various amounts of AE on the improvement of HRV, inflammatory markers, and insulin resistance among community residents with overweight/obesity.

Methods: A randomized control trial with purposive sampling will be used to recruit community residents aged 40-64 years with inactive habits in southern Taiwan. To obtain the targeted sample size of 96 participants, including 42 participants with normal weight and 54 participants with overweight, the study will conduct three recruitment waves and 16-week interventions. The participants with normal weight will be further randomly allocated to a group receiving AE training with at least moderate intensity three times per week or a control group, whereas the participants with overweight will be randomly allocated to a group receiving the same prescribed AE training three times per week, a group receiving AE training five times per week (with additional home-based exercise two times per week), or a control group. HRV parameters, blood samples, and visceral fat will be evaluated. The blood samples will be evaluated for adipocytokines (adiponectin and leptin), proflammatory cytokines (interleukin-1 and interleukin-6), and markers of insulin resistance (fasting glucose, insulin, glucagon-like peptide-1, and dipeptidyl peptidase-4). All participants will be evaluated at baseline (T0) and after a 16- week intervention (T1). In addition to these time points, HRV will be measured during every exercise session for participants in exercise groups. Generalized estimating equations will be used to determine whether baseline BMI is the key factor influencing the effects of AE and whether higher exercise amounts contribute to greater improvements in HRV in the overweight group. Relevance to clinical practice: The findings will serve as a reference for clinical professionals to promote exercise among the general population and will provide evidence of whether different exercise amounts are recommended for individuals with different BMIs for improving HRV.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: July 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 64 Years

Eligibility

Inclusion Criteria:

• are aged between 40 and 64 years.

• had inactive habit (<3 days of physical activity per week and <30 minutes per session).

• can communicate in Mandarin or Taiwanese.

Exclusion Criteria:

• underlying conditions, such as stroke, acute coronary artery diseases, handicap, pregnancy, and unstable hypertension, that may present risks for exercise training.

• smoking or alcohol abuse.

• currently being on a diet, and (d) lifestyles that may affect HRV and inflammatory biomarkers (e.g., shift work or habit of staying up late).

Related Conditions & MeSH terms

• Inflammation
• Insulin Resistance
• Obesity
• Overweight

Intervention

Behavioral:
• aerobic exercise(AE)
The participants in Groups A and C will receive AE three times per week, and those in Group D will receive AE five times per week (the same supervised AE protocol three times a week with additional home-based AE training with an instructional video two times a week). The exercise movements in the instructional video will be identical to those of the supervised exercise to enable the participants to easily perform the exercise at home. The participants in the two control groups (Groups B and E) will maintain their original lifestyle without any exercise intervention during the 16 weeks.

Locations

Country	Name	City	State
Taiwan	Yu-Hsuan Chang	Tainan

Sponsors (1)

Lead Sponsor	Collaborator
National Tainan Junior College of Nursing

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Heart rate variability	will use heart rate variability analyzer	two times and each session of exercise (change from baseline to the end of 16-week)
Primary	insulin resistance	µIU/mL	two times (change from baseline to the end of 16-week)
Primary	Visceral fat	will use body composition analyzer	two times (change from baseline to the end of 16-week)
Primary	fasting glucose	mg/dL	two times (change from baseline to the end of 16-week)
Primary	C-reactive protein	mg/L	two times (change from baseline to the end of 16-week)
Primary	Waist-to-hip ratio	Waist-to-hip ratio	two times (change from baseline to the end of 16-week)
Primary	Waist-to-height ratio	Waist-to-height ratio	two times (change from baseline to the end of 16-week)
Primary	body weight	weight in Kilogram	two times (change from baseline to the end of 16-week)
Primary	BMI	weight and height will be combined to report BMI in kg/m^2	two times (change from baseline to the end of 16-week)